Prosecution Insights
Last updated: August 15, 2026

Sutro Biopharma Inc.

6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
6
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (33%)
4
Easy (67%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only1 (17%)
§112 only4 (67%)
Double-patenting + other1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
83% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
17% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HUYNH, PHUONG N 2 65.7% +53.6%
JACKSON, SHAWQUIA 1 77.9% -3.3%
HOWARD, ZACHARY C 1 63.8% +38.0%
GALSTER, SAMUEL LEONARD 1 52.3% +41.7%
ESSEX, LAURA ANN 1 59.6% +36.8%

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17276757 COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES ESSEX, LAURA ANN 46d overdue
17727395 ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE HUYNH, PHUONG N 2d overdue
18426426 ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE HUYNH, PHUONG N
18357956 ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES HOWARD, ZACHARY C
18215093 BETA-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF GALSTER, SAMUEL LEONARD

Top Art Units

Art UnitApps
1641 2
1674 1
1693 1
1675 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18789214 STING AGONIST COMPOUNDS AND CONJUGATES JACKSON, SHAWQUIA §102 Non-Final OA Pending Jul 30, 2024
18426426 ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE HUYNH, PHUONG N 1641 §112Other Non-Final OA Pending Jan 30, 2024
18357956 ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES HOWARD, ZACHARY C 1674 §112Other Non-Final OA Pending Jul 24, 2023
18215093 BETA-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF GALSTER, SAMUEL LEONARD 1693 §103DP Non-Final OA Pending Jun 27, 2023
17727395 ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE HUYNH, PHUONG N 1641 §112Other Non-Final OA 2d overdue Pending Apr 22, 2022
17276757 COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES ESSEX, LAURA ANN 1675 §112 Non-Final OA 46d overdue Pending Mar 16, 2021

Managing Sutro Biopharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month